ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 081 • 2023 Pediatric Rheumatology Symposium

    Predicting Extension in Juvenile Idiopathic Arthritis

    Megan Simonds1, Kathleen Sullivan2 and AnneMarie Brescia1, 1Nemours Children's Health, Wilmington, DE, 2Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and carries a risk of permanent joint damage and disability [1]. In…
  • Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium

    Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative

    Jayne MacMahon1, Jeanine McColl2, Alaa Al-Shehab1, Deborah Levy3, Ronald laxer1 and Shirley Tse1, 1University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 2University of Alberta, Edmonton, AB, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
  • Abstract Number: 094 • 2023 Pediatric Rheumatology Symposium

    Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis

    Anna Costello1, Marinka Twilt2 and Melissa Lerman1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Alberta Children's Hospital, Calgary, AB, Canada

    Background/Purpose: TM joint arthritis is an underrecognized complication of JIA that can cause long-term problems including decreased mandibular growth, altered facial morphology, and orofacial pain.…
  • Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium

    Quality Improvement Lessons in a New Practice

    Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar

    Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
  • Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium

    Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

    Claudia Bracaglia1, Francesca Minoia2, Christoph Kessel3, Sebastiaan Vastert4, Manuela Pardeo1, Alessia Arduini1, Sarka Fingerhutova5, Irina Nikishina6, Ozge Basaran7, Nural Kiper8, Mikhail Kostik9, Mia Glerup10, Roberta Caorsi11, AnnaCarin Horne12, Giovanni Filocamo2, Helmut Wittkowski3, Marija Jelusic13, Jordi Anton14, Samira Khaldi-Plassart15, Alexandre Belot15, Gerd Horneff16, Seraina Palmer Sarrott17, Elvira Cannizzaro Schneider18, Lampros Fotis19, Pavla Dolezalova5, Angelo Ravelli20, Seza Ozen7 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milano, Italy, 3Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Muenster, Germany, 4Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 5Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, 6V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 8Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, 9Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 11Department of Pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, 12Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, 13Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia, 14Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, 15Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, 16Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 17Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Zurich, Switzerland, 18Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Switzerland, 19Pediatric Rheumatology Division, 3rd Department of Pediatrics, National and Kapodistrian University of Athens,‘’ATTIKON’’ General University Hospital, Athens, Greece, 20IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy

    Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
  • Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium

    Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative

    Dori Abel1, Joyce Chang2, Jon Burnham3, Chen Kenyon4 and Sabrina Gmuca5, 1Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, 2Boston Children's Hospital, Boston, MA, 3Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
  • Abstract Number: 097 • 2023 Pediatric Rheumatology Symposium

    Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease

    Mariana Correia Marques1, Paul Subrata2, Carol Lake3, Ly-Lan Bergeron4, Rashmi Sinha5, Luciana Peixoto6, Marinka Twilt7 and Michael Ombrello8, 1Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases/Children`s National Hospital, Bethesda, MD, 2NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3NIH, GAITHERSBURG, MD, 4NIH/NIAMS, Vienna, VA, 5Systemic JIA Foundation, Cincinnati, OH, 6Systemic JIA Foundation, Cincinnati, 7Alberta Children's Hospital, Calgary, AB, Canada, 8Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD

    Background/Purpose: Immunization is one of the most important tools for the control of the Covid-19 pandemic. The safety and effectiveness of the Covid-19 immunizations have…
  • Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium

    Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea

    Je Hee Shin1, Jung Yoon Pyo2, Minkyung Han3, Myeongjee Lee3, Sung Min Lim1, Jee Yeon Baek1, Ji Young Lee1, Ji-Man Kang1, InKyung Jung3 and Jong Gyun Ahn1, 1Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, 3Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
  • Abstract Number: 102 • 2023 Pediatric Rheumatology Symposium

    Preliminary Results from a Survey of Psychological Resilience Among JIA Patients

    Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Psychological resilience – an individuals capacity to adapt in the face of stressors and recover after adverse events – has been linked to a…
  • Abstract Number: 003 • 2023 Pediatric Rheumatology Symposium

    Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis

    Emily Hause, Abdirazak Ali and Muna Sunni, University of Minnesota, Minneapolis, MN

    Background/Purpose: Data regarding the linguistic and cultural factors impacting the Somali patient experience and understanding with regards to juvenile idiopathic arthritis (JIA) are limited. We…
  • Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium

    Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients

    Ana Isabel Rebollo-Giménez1, Luca Carlini2, Yulia Vyzhga3, Silvia Rosina4, Ekaterina Alexeeva5, Charlotte Myrup6, Silvia Magni Manzoni7, Maria Trachana8, Valda Stanevicha9, Constantin Ailioaie10, Elena Tsitsami11, Alexis-Virgil Cochino12, Chiara Pallotti13, Silvia Scala13, Angela Pistorio14, Sebastiaan Vastert15, Joost F. Swart16 and Nicolino Ruperto17, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, 3IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, 4IRCCS Istituto Giannina Gaslini, Genova, Italy, 5Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, 6Rigshospitalet, Pediatric rheumatology unit 4272, Copenhagem, Denmark, 7IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, Roma, Italy, 8Hippokration General Hospital, Thessaloniki University School of Medicine, First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Thessaloniki, Greece, 9Riga Stradins University, Children University Hospital, Riga, Latvia, 10Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 11Aghia Sophia Childrens Hospital, First Department of Pediatrics, University of Athens Medical School, Athens, Greece, 12Institute for Mother and Child Care, Pediatrics, Bucharest, Romania, 13IRCCS Istituto Giannina Gaslini, U.O.C. Pediatric and Rheumatology Clinic, PRINTO, Genova, Italy, 14IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, 15Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 16Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, Netherlands, 17IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, PRINTO, Genova, Italy

    Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…
  • Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium

    Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment

    Esraa Eloseily1, Alex Pickering2, Sanjeev Dhakal3, Alexei Grom3, Hermine Brunner3 and Sherry Thornton4, 1Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnti, OH, 2Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…
  • Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium

    Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

    Itay Marmor1, Rotem Semo Oz2, Amir hendel3, Guy Hazan4, Kevin Baszis5, Anthony French5, Cuoghi Edens6, Irit Tirosh7, Yonatan Butbul Aviel8, Liora Harel9 and Gil Amarilyo10, 1Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 2Sheba medical center, Herzelyia, Israel, 3Tel Aviv University, Tel Aviv, Israel, 4Soroka University Medical Center, Be'er Sheva, Israel, 5Washington University School of Medicine, St Louis, MO, 6University of Chicago, Chicago, IL, 7Sheba Medical Center, Savyon, Israel, 8Rambam Medical center, Haifa, Israel, 9Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, 10Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
  • Abstract Number: 017 • 2023 Pediatric Rheumatology Symposium

    Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study

    Tiffany Nguyen1, Ilaria Maccora1, Mekibib Altaye1, Wendy Haffey2, Theresa Hennard1, Alyssa Sproles1, Sherry Thornton1, Virginia Miraldi Utz1, Ken Greis2 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital, Cincinnati, OH, 2University of Cincinnati, Cincinnati, OH

    Background/Purpose: Children diagnosed with oligoarticular juvenile idiopathic arthritis (JIA), the most commonly diagnosed subset of chronic arthritis, are at increased risk of developing uveitis. Known…
  • Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium

    Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis

    Alysha Taxter1, Marc Natter2, Min-Lee Chang2, Laura Schanberg3, Valarie Morrow4, Eveline Wu5, Tedryl Bumpass4, Alex Fist4, Meg Waite6, Vincent Del Gaizo7, Melanie Kohlheim7 and CARRA Registry Investigators7, 1Nationwide Children's Hospital, Columbus, OH, 2Boston Children's Hospital, Boston, MA, 3Duke University Medical Center, Durham, NC, 4Duke University, Durham, NC, 5UNC Chapel Hill, Chapel Hill, NC, 6Boston Children's Hospital, Boston, MA, 7CARRA, Washington, DC

    Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology